236 related articles for article (PubMed ID: 23507740)
1. Adaptive designs for dual-agent phase I dose-escalation studies.
Harrington JA; Wheeler GM; Sweeting MJ; Mander AP; Jodrell DI
Nat Rev Clin Oncol; 2013 May; 10(5):277-88. PubMed ID: 23507740
[TBL] [Abstract][Full Text] [Related]
2. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
Mozgunov P; Jaki T; Paoletti X
J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
[TBL] [Abstract][Full Text] [Related]
3. Modelling semi-attributable toxicity in dual-agent phase I trials with non-concurrent drug administration.
Wheeler GM; Sweeting MJ; Mander AP; Lee SM; Cheung YK
Stat Med; 2017 Jan; 36(2):225-241. PubMed ID: 26891942
[TBL] [Abstract][Full Text] [Related]
4. A product of independent beta probabilities dose escalation design for dual-agent phase I trials.
Mander AP; Sweeting MJ
Stat Med; 2015 Apr; 34(8):1261-76. PubMed ID: 25630638
[TBL] [Abstract][Full Text] [Related]
5. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
Tighiouart M; Li Q; Rogatko A
Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalation models for combination phase I trials in oncology.
Hamberg P; Ratain MJ; Lesaffre E; Verweij J
Eur J Cancer; 2010 Nov; 46(16):2870-8. PubMed ID: 20691584
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II adaptive design for drug combination oncology trials.
Wages NA; Conaway MR
Stat Med; 2014 May; 33(12):1990-2003. PubMed ID: 24470329
[TBL] [Abstract][Full Text] [Related]
8. Design issues in dose-finding Phase I trials for combinations of two agents.
Fan SK; Venook AP; Lu Y
J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
[TBL] [Abstract][Full Text] [Related]
9. Two-stage approach based on zone and dose findings for two-agent combination Phase I/II trials.
Shimamura F; Hamada C; Matsui S; Hirakawa A
J Biopharm Stat; 2018; 28(6):1025-1037. PubMed ID: 29420127
[TBL] [Abstract][Full Text] [Related]
10. A Bayesian adaptive Phase I-II clinical trial for evaluating efficacy and toxicity with delayed outcomes.
Koopmeiners JS; Modiano J
Clin Trials; 2014 Feb; 11(1):38-48. PubMed ID: 24082004
[TBL] [Abstract][Full Text] [Related]
11. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
Braun TM; Alonzo TA
Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
[TBL] [Abstract][Full Text] [Related]
12. Methodologic guidelines for the design of high-dose chemotherapy regimens.
Margolin K; Synold T; Longmate J; Doroshow JH
Biol Blood Marrow Transplant; 2001; 7(8):414-32. PubMed ID: 11569887
[TBL] [Abstract][Full Text] [Related]
13. Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.
Pierrillas PB; Fouliard S; Chenel M; Hooker AC; Friberg LE; Karlsson MO
AAPS J; 2018 Mar; 20(2):39. PubMed ID: 29516207
[TBL] [Abstract][Full Text] [Related]
14. Application of Bayesian hierarchical models for phase I/II clinical trials in oncology.
Yada S; Hamada C
Pharm Stat; 2017 Mar; 16(2):114-121. PubMed ID: 27892650
[TBL] [Abstract][Full Text] [Related]
15. Adaptive dose selection using efficacy-toxicity trade-offs: illustrations and practical considerations.
Thall PF; Cook JD; Estey EH
J Biopharm Stat; 2006; 16(5):623-38. PubMed ID: 17037262
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian phase I-II clinical trial design to find the biological optimal dose on drug combination.
Wang Z; Zhang J; Xia T; He R; Yan F
J Biopharm Stat; 2024 Jul; 34(4):582-595. PubMed ID: 37461311
[TBL] [Abstract][Full Text] [Related]
17. On the coherence of model-based dose-finding designs for drug combination trials.
Park Y; Liu S
PLoS One; 2020; 15(11):e0242561. PubMed ID: 33253260
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation methods in phase I cancer clinical trials.
Le Tourneau C; Lee JJ; Siu LL
J Natl Cancer Inst; 2009 May; 101(10):708-20. PubMed ID: 19436029
[TBL] [Abstract][Full Text] [Related]
19. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Tighiouart M; Piantadosi S; Rogatko A
Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
[TBL] [Abstract][Full Text] [Related]
20. A Dose-Finding Method Based on Multiple Dosing in Two-Agent Combination Phase I Trials.
Kakurai Y; Hirakawa A; Hamada C
J Biopharm Stat; 2015; 25(5):1065-76. PubMed ID: 25369852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]